Pharmacologic Augmentation of TMS for Depression With D-serine
NCT: NCT06876129 · RECRUITING
Brief Summary
The goal of this study is to test whether combining D-serine with 30 treatments of a) iTBS and b) 18-Hz protocols will enhance clinical outcomes compared to rTMS with placebo (i.e., sugar pill). The investigators hypothesize that NMDA receptor activation via D-serine combined with repeated sessions of rTMS will produce greater clinical outcomes than iTBS with placebo and 18-Hz with placebo.
Frequently Asked Questions
What is Pharmacologic Augmentation of TMS for Depression With D-serine?
Pharmacologic Augmentation of TMS for Depression With D-serine is a clinical trial registered under NCT06876129. Current status: RECRUITING.
What is the status of NCT06876129?
The current status of NCT06876129 (Pharmacologic Augmentation of TMS for Depression With D-serine) is: RECRUITING.
When did Pharmacologic Augmentation of TMS for Depression With D-serine start?
Pharmacologic Augmentation of TMS for Depression With D-serine started on 2025-04-01.
Official Source
View on ClinicalTrials.gov →Data sourced from ClinicalTrials.gov API. For the most current status, refer to the official record.